Advertisement
Table 2 The clinical characteristics of the 220 non-small cell lung cancer (NSCLC) patients
| Variate | Number of patients [cases (%)] |
|---|---|
| Total | 220 |
| Age (years) | |
| ≤55 | 93 (42.3) |
| >55 | 127 (57.7) |
| Smoking status | |
| Never | 95 (43.2) |
| Ever | 125 (56.8) |
| Gender | |
| Male | 165 (75.0) |
| Female | 55 (25.0) |
| ECOG PS | |
| 0–1 | 39 (17.7) |
| 2 | 181 (82.3) |
| Histological type | |
| Adenocarcinoma | 108 (49.1) |
| Squamous cell carcinoma | 112 (50.9) |
| Stage | |
| I–II | 8 (3.6) |
| III–IV | 212 (96.4) |
| Platinum-based drug | |
| Cisplatin | 37(16.8) |
| Carboplatin | 183 (83.2) |
| Chemotherapy regimen | |
| Platinum-gemcitabine | 112 (50.9) |
| Platinum-pemetrexed | 68 (30.9) |
| Platinum-paclitaxel | 23 (10.4) |
| Platinum-docetaxel | 12 (5.5) |
| Platinum-navelbine | 5 (2.3) |
| Severe toxicity | |
| Total | 79 (35.9) |
| Hematologic toxicity | 55 (25.0) |
| Gastrointestinal toxicity | 31 (14.1) |
